Biomapas Has Acquired Safety Tech Firm Pinnaxis
The acquisition expands Biomapas’ pharmacovigilance capabilities and adds over 100 technical experts.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you believe corporate acquisitions generally improve the services provided to customers?
Biomapas has acquired the India-based technology firm Pinnaxis to bolster its drug safety and pharmacovigilance software portfolio. The deal merges teams across multiple international offices to advance automated safety data processing.
Why it matters
This move signals a strategic consolidation in the life sciences technology sector, as firms race to integrate automated safety monitoring and data migration tools. It enables Biomapas to scale its U.S. presence while enhancing its capacity for managing complex drug safety reporting.
Pinnaxis contributes proprietary tools designed for automating safety data migration and case intake. These systems support major industry platforms such as Veeva Safety Vault, Oracle Argus, and ArisGlobal.
The players
Biomapas
A clinical research organization with offices in Lithuania and Luxembourg that focuses on providing drug safety and consulting services.
Pinnaxis
A Noida, India-based technology company providing software expertise for pharmacovigilance and drug safety automation.
Carbyne Equity Partners
An investment firm that has served as the majority shareholder of Biomapas since October 2024.
The details
Pinnaxis operates as a service provider for pharmaceutical companies, specifically targeting the automation of pharmacovigilance—the practice of monitoring the effects of medical drugs after they have been licensed for use. By integrating these proprietary automation tools, Biomapas aims to reduce manual errors in safety data reporting. The combined entity will leverage the existing expertise in Veeva Safety Vault, a cloud-based software for life sciences, and Oracle Argus, a specialized drug safety database.
Timeline
2018: Pinnaxis was founded.
October 2024: Carbyne Equity Partners became the majority shareholder of Biomapas.
2025: Biomapas acquired Delta PV.
October 6, 2026: Biomapas announced the acquisition of Pinnaxis.
The Tech Race
This acquisition follows a broader industry trend toward the consolidation of pharmacovigilance technology services. By absorbing Pinnaxis, Biomapas seeks to close the gap on competitors that rely on proprietary automation to handle increasing volumes of drug safety data.
Biomapas customers can expect integration of new automation workflows into their existing drug safety platforms in the coming months. The company intends to merge teams across its international offices to provide a unified service offering.
The takeaway
The acquisition highlights the necessity for clinical firms to maintain deep technical expertise in automated drug safety reporting. Industry observers should watch for the integration progress of Biomapas and the scaling of its U.S.-based operations over the next fiscal year.
Further reading
For more on the changing landscape of medical oversight tools, see Biotech.
Source note: This article includes information reported by Pharmafocusasia.
Live Poll
Do you believe corporate acquisitions generally improve the services provided to customers?
